October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] READ MORE
September 18, 2019 The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva®) for adults with lupus nephritis – the most common complication of lupus. The FDA’s designation aims to speed up the development and review of drugs intended to treat a serious condition […] READ MORE
MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019. Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […] READ MORE
April, 2019 As our name implies, the Lupus Research Alliance aims to forge partnerships and bring other players to the table to better understand and treat lupus — and our latest venture holds the promise of a new therapy. We — and our affiliate, Lupus Therapeutics — are about to collaborate with Takeda Pharmaceutical Company […] READ MORE
A new study funded by the Lupus Nephritis Trials Network with support from the Lupus Research Alliance has proposed a set of standardized measures that promise to improve the way clinical trials in lupus nephritis (LN) are structured and how clinical researchers report their results. The findings will also help researchers in their search for […] READ MORE
New York, NY– March 1. The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916). The national study will be conducted in 20 research centers throughout the country, many […] READ MORE
NEW YORK, NY. February 19. Pieces of bacteria that escape from the intestines may trigger lupus and associated disease flares in some patients, according to a new study partly funded by the Lupus Research Alliance. These findings may allow disease treatment with probiotics or diets that alter the mix of bacterial species in the intestines. […] READ MORE
In 2018 the Lupus Research Alliance has taken daring chances, pursued bold initiatives, and made tremendous strides! We truly are breaking through on many pioneering fronts of lupus research — thanks to the unwavering generosity of donors at all levels of support. Throughout the year, the brilliant scientists we brought to the table ushered in […] READ MORE
December, 2018 An innate — and lifelong — curiosity about the most complex, unresolved questions in medicine has served John D. Mountz, MD, PhD, from the University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, well. For the past three decades he has made significant strides in piecing together some of the most […] READ MORE
The Lupus Research Alliance supports the full range of research from fundamental through translational and clinical studies. Most recently, the organization awarded six Novel Research Grants and seven Target Identification in Lupus (TIL) grants. PROMISING NOVEL GRANT AWARDS: The Lupus Research Alliance supports game-changing lupus research, and our Novel Research Grant program is exploring lupus […] READ MORE
October 29, 2018 More than 70 researchers who have received funding from the Lupus Research Alliance contributed to the scientific dialogue on lupus at the ACR|ARHP meeting this year. Following are highlights of specific discoveries the organization has supported: Tiring Out Rogue Cells Learning from cancer research, a team of scientists led by the inaugural […] READ MORE
October 4, 2018 Abnormal immune cells invade the kidneys in patients with lupus and can damage the organs so severely that they stop working. But the kidneys defend themselves from these attacks by disabling these rogue cells, according to a new study from two scientists funded by the Lupus Research Alliance. Cancerous tumors similarly protect […] READ MORE
